Will the CSL share price crack the $300 barrier this week?

The CSL Limited (ASX: CSL) share price could break the $300 barrier this week – is there still time to buy the healthcare group for growth?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has started the new decade exactly how it finished the last – rocketing higher.

The healthcare group's shares closed at $299.30 per share last Friday and set a new all-time high in the process.

Why you should watch the CSL share price this week

There's a good chance the CSL share price could finally breach the $300 per share barrier for the first time ever.

That would be an impressive start to the new year, given the healthcare group's shares are up a whopping 38,973% since its IPO.

CSL listed on the ASX in 1994 for an adjusted 3-for-1 stock split price of just 76.6 cents per share. That means an investor who bought and held $10,000 worth of CSL shares since the IPO would be sitting on $3,897,310.70 today.

Of course, most investors would have sold their shares well short of today's all-time high. But if you were a true long-term buy-and-hold investor, that is a very tidy return from the CSL share price.

Where can I find the next CSL?

That is the multi-million-dollar question everyone would love an answer to. There have been several strong ASX growth shares emerge in recent years, all of which have potential.

The most notable ones are the "WAAAX" tech shares including Altium Limited (ASX: ALU), Appen Ltd (ASX: APX) and Xero Limited (ASX: XRO), which have seen similar growth trajectories to the CSL share price.

Outside of these, Nearmap Ltd (ASX: NEA) shares have rocketed higher in the past decade, and it has been a similar story for buy-now, pay-later companies like Zip Co Ltd (ASX: Z1P) and Afterpay Ltd (ASX: APT).

How can I make huge returns on the ASX?

To make the really big money and cash in on share price rises like CSL, you really have to be an IPO investor.

That is more difficult than you think, with evidence showing that you're likely to lose money by investing in IPOs in the long-term.

Of course, if you can ride a winner like CSL all the way to the top, you may only need one ASX growth stock to make your retirement plans a reality.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO, CSL Ltd., and ZIPCOLTD FPO. The Motley Fool Australia owns shares of and has recommended Nearmap Ltd. The Motley Fool Australia owns shares of Altium and Xero. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Could CSL shares outperform the ASX 200 in 2026?

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better.

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Healthcare Shares

Why did CSL shares crash 39% in 2025?

Should you be buying the dip? Let's find out.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Why 4DMedical shares are jumping 14% today

4DMedical shares climb on a new CFO appointment as investors focus on US expansion and rising use of its lung…

Read more »

A business woman flexes her muscles overlooking a city scape below.
Healthcare Shares

Why I plan to buy this incredible ASX 200 stock in 2026

A 33% pullback has put Pro Medicus back in focus. Here’s why I’m preparing to buy its shares in 2026.

Read more »

research with microscope
Healthcare Shares

This ASX healthcare stock just changed its debt. Here's why it matters

Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure.

Read more »

stock growth chart
Healthcare Shares

Will CSL shares crash again in 2026?

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Mayne Pharma signals short-term pain as it resets for growth

It has been a turbulent year for Mayne Pharma after the terminated takeover bid by US company Cosette Pharmaceuticals.

Read more »